Results 271 to 280 of about 226,651 (317)

Management of Latent Tuberculosis Infection

open access: yesJAMA, 2023
This JAMA Insights Clinical Update examines treatment recommendations and therapy options among adults with latent tuberculosis infection.
Steven, Kim   +2 more
openaire   +3 more sources

Latent Tuberculosis Infection

New England Journal of Medicine, 2021
Tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis. Latent tuberculosis infection (LTBI) occurs when M. tuberculosis is present in the body without signs and symptoms, or evidence of TB disease.
Maunank, Shah, Susan E, Dorman
openaire   +3 more sources

Diagnostic Tests for Latent Tuberculosis Infection

Clinics in Chest Medicine, 2019
Diagnosing latent tuberculosis (TB) infection (LTBI) is important globally for TB prevention. LTBI diagnosis requires a positive test for infection and negative evaluation for active disease. Current tests measure an immunologic response and include the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), T-SPOT.TB and QuantiFERON ...
Michelle K, Haas, Robert W, Belknap
openaire   +3 more sources

Latent Mycobacterium tuberculosis Infection

New England Journal of Medicine, 2015
The natural history of tuberculosis begins with the inhalation of Mycobacterium tuberculosis organisms; a period of bacterial replication and dissemination ensues, followed by immunologic containment of viable bacilli. The result of this process is asymptomatic latent tuberculosis infection, which is defined as a state of persistent bacterial viability,
Getahun, Haileyesus   +3 more
openaire   +8 more sources

Treatment of Latent Tuberculosis Infection

Annals of Internal Medicine, 2015
possible comparisons, 42 (40%) were compared directly. Compared with placebo, isoniazid for 6 months (odds ratio [OR], 0.64 [95% credible interval {CrI}, 0.48 to 0.83]) or 12 months or longer (OR, 0.52 [CrI, 0.41 to 0.66]), rifampicin for 3 to 4 months (OR, 0.41 [CrI, 0.18 to 0.86]), rifapentine-isoniazid (OR, 0.61 [CrI, 0.29 to 1.22]), and rifampicin ...
Dominik, Zenner   +3 more
  +7 more sources

Latent Tuberculosis Infection

Seminars in Respiratory and Critical Care Medicine, 2004
Latent tuberculosis infection (LTBI) is a clinical condition characterized by a positive tuberculin skin test in the absence of clinical or radiological signs of active tuberculosis disease. It has been estimated that one third of the world's population is latently infected with Mycobacterium tuberculosis and serves as an enormous reservoir for future ...
Eric, Nuermberger   +2 more
openaire   +2 more sources

Treatment of latent tuberculosis infection

Seminars in Respiratory Infections, 2003
Treatment of latent tuberculosis infection (LTBI) is considered an essential component of TB control programs in several industrialized countries and is being used in selected situations in developing countries. In 2000, the American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) published new recommendations on the ...
DE ROSA, Francesco Giuseppe   +1 more
openaire   +3 more sources

Latent Tuberculosis Infection and BCG Vaccination

Journal of Midwifery & Women's Health, 2005
One third of the world's population is infected with Mycobacterium tuberculosis, and 5% to 10% of those infected will develop active disease. Identification and treatment of latent tuberculosis infection (LTBI) is an essential part of the public health strategy to control the spread of TB.
Lisa, Ross, Meredith, Goff
openaire   +2 more sources

Home - About - Disclaimer - Privacy